GRAND is a Pfizer-supported independently reviewed competitive grants program awarding individual grants of up to $200,000 from a total fund in 2017 of $1 million to support projects which directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Of 486 applications received since 2008, 62 grants have been awarded.
Pfizer has called for Clinical research proposals that aim to increase the understanding of the mechanisms of tobacco and nicotine dependence and its treatment. The overall mission of the GRAND program is to advance the pharmacological treatment of tobacco and nicotine dependence.
Each proposal should fall into one of the following areas:
- Human laboratory (e.g., pharmacokinetics, pharmacodynamics, cravings, withdrawal);
- Pharmacotherapy of smoking cessation and relapse, and / or its interaction with behavioral support;
- Characterization of subtypes of smokers; suitability for appropriate interventions.
Research projects should aim to provide information that could directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Examples could include:
- Observational or interventional studies of pharmacotherapy
- Optimization of the use of currently available medication
- Effectiveness of pharmacotherapy in real-life settings
- Development or use of new medications for cessation or harm reduction
- Specifically designed pharmacotherapy in subtypes of tobacco/nicotine users
- Use of existing databases to inform the clinical use of pharmacotherapy
- Policy interventions to increase use of pharmacotherapy.
The intent of the program is to fund at least 6 awards of between $50,000 and $200,000 in value, totaling $1.2 million. The awards are open to all investigators and they would strongly encourage applications from junior investigators.
Applications will be formally assessed by, and only by, the GRAND Review Committee, an independent committee comprising internationally prominent researchers in the field. The final responsibility for selection of Awardees rests with the Co-Chairs of the Review Committee, John Hughes and Karl Fagerstrom. The whole process is completely independent of Pfizer, including the final selection of Awardees.
GRAND is open to all investigators from around the world holding an MD, a PhD, or equivalent.
Application deadline: July 3, 2017